Sedat Gül/LinkedIn
Sep 5, 2026, 02:44
Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
Sedat Gül, Assistant Professor at University of Nebraska Medical Center, shared a post on LinkedIn:
“I had the opportunity to comment in Annals of Internal Medicine on the TAPIS trial, which revisits the timing of antiplatelet therapy after thrombolysis in acute ischemic stroke.
While the findings may not be directly generalizable to the U.S. stroke population, TAPIS provides solid safety data and a signal of potential benefit with earlier initiation of antiplatelet therapy.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026